BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27268204)

  • 1. Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.
    Luo H; Schmidt JA; Lee YS; Oltz EM; Payton JE
    Leuk Lymphoma; 2017 Feb; 58(2):445-456. PubMed ID: 27268204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
    Ci W; Polo JM; Cerchietti L; Shaknovich R; Wang L; Yang SN; Ye K; Farinha P; Horsman DE; Gascoyne RD; Elemento O; Melnick A
    Blood; 2009 May; 113(22):5536-48. PubMed ID: 19307668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.
    Perez-Rosado A; Artiga M; Vargiu P; Sanchez-Aguilera A; Alvarez-Barrientos A; Piris M
    J Pathol; 2008 Mar; 214(4):498-507. PubMed ID: 18189332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
    Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
    Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
    Fan Q; Meng X; Liang H; Zhang H; Liu X; Li L; Li W; Sun W; Zhang H; Zen K; Zhang CY; Zhou Z; Chen X; Ba Y
    Protein Cell; 2016 Dec; 7(12):899-912. PubMed ID: 27815824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis.
    Baron BW; Anastasi J; Thirman MJ; Furukawa Y; Fears S; Kim DC; Simone F; Birkenbach M; Montag A; Sadhu A; Zeleznik-Le N; McKeithan TW
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2860-5. PubMed ID: 11854457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
    Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
    Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.
    Jiao J; Lv Z; Zhang P; Wang Y; Yuan M; Yu X; Otieno Odhiambo W; Zheng M; Zhang H; Ma Y; Ji Y
    Neoplasia; 2020 Mar; 22(3):142-153. PubMed ID: 32062068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
    Franco R; Scognamiglio G; Valentino E; Vitiello M; Luciano A; Palma G; Arra C; La Mantia E; Panico L; Tenneriello V; Pinto A; Frigeri F; Capobianco G; Botti G; Cerchia L; De Chiara A; Fedele M
    Oncotarget; 2016 Sep; 7(37):59158-59172. PubMed ID: 27494852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.
    Bal E; Kumar R; Hadigol M; Holmes AB; Hilton LK; Loh JW; Dreval K; Wong JCH; Vlasevska S; Corinaldesi C; Soni RK; Basso K; Morin RD; Khiabanian H; Pasqualucci L; Dalla-Favera R
    Nature; 2022 Jul; 607(7920):808-815. PubMed ID: 35794478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.
    Kuai Y; Gong X; Ding L; Li F; Lei L; Gong Y; Liu Q; Tan H; Zhang X; Liu D; Ren G; Pan H; Shi Y; Berberich-Siebelt F; Mao Z; Zhou R
    Cell Commun Signal; 2018 Aug; 16(1):50. PubMed ID: 30143009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
    Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
    Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Critical Role of miR-144 in Diffuse Large B-cell Lymphoma Proliferation and Invasion.
    Wang H; Wang A; Hu Z; Xu X; Liu Z; Wang Z
    Cancer Immunol Res; 2016 Apr; 4(4):337-44. PubMed ID: 26865454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.
    Iqbal J; Greiner TC; Patel K; Dave BJ; Smith L; Ji J; Wright G; Sanger WG; Pickering DL; Jain S; Horsman DE; Shen Y; Fu K; Weisenburger DD; Hans CP; Campo E; Gascoyne RD; Rosenwald A; Jaffe ES; Delabie J; Rimsza L; Ott G; Müller-Hermelink HK; Connors JM; Vose JM; McKeithan T; Staudt LM; Chan WC;
    Leukemia; 2007 Nov; 21(11):2332-43. PubMed ID: 17625604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus.
    Batlle-López A; Cortiguera MG; Rosa-Garrido M; Blanco R; del Cerro E; Torrano V; Wagner SD; Delgado MD
    Oncogene; 2015 Jan; 34(2):246-56. PubMed ID: 24362533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma].
    Zhang XY; Ma ZP; Cui WL; Chen R; Glinaer A; Miao N; Li XX
    Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):831-837. PubMed ID: 28056297
    [No Abstract]   [Full Text] [Related]  

  • 18. miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model.
    Sandhu SK; Volinia S; Costinean S; Galasso M; Neinast R; Santhanam R; Parthun MR; Perrotti D; Marcucci G; Garzon R; Croce CM
    Proc Natl Acad Sci U S A; 2012 Dec; 109(49):20047-52. PubMed ID: 23169640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Point mutations in BCL6 DNA-binding domain reveal distinct roles for the six zinc fingers.
    Mascle X; Albagli O; Lemercier C
    Biochem Biophys Res Commun; 2003 Jan; 300(2):391-6. PubMed ID: 12504096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.
    Parekh S; Privé G; Melnick A
    Leuk Lymphoma; 2008 May; 49(5):874-82. PubMed ID: 18452090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.